Full text
Integration of palliative care in advanced heart failure: a narrative review of clinical outcomes, symptom burden, and implementation strategies
Jan Mikulicz-Radecki University Clinical Hospital, Wroclaw, Poland
Regional Specialist Hospital in Wroclaw, Research and Development Center, Wroclaw, Poland
Henryk Klimontowicz Specialist Hospital, Gorlice, Poland
University of Opole, Opole, Poland
Jozef Strus Multispecialist Municipal Hospital with a Long-Term Care Facility, Independent Public Health Care Institution, Poznan, Poland
Ludwik Rydygier Regional Integrated Hospital, Torun, Poland
St. Vincent de Paul Municipal Hospital, Gdynia, Poland
Jagiellonian University Medical College, Cracow, Poland
Medycyna Paliatywna 2026; 18(3): 149–157
Introduction
Heart failure (HF) has become a worldwide epidemic which creates significant public health issues because of population aging [1]. This projected increase in HF cases will create an enormous burden for healthcare facilities while simultaneously affecting the life quality of patients together and their family members [2, 3]. Disease progression of HF follows an unpredictable path which distinguishes it from other chronic medical conditions [4]. Such progression shows a steady deterioration of patient function until it triggers sudden acute worsening which makes it challenging to predict patient outcomes and develop appropriate treatment plans [5]. Consequently, the development of new cardiac treatments which improve survival rates has led to an increasing number of patients who must endure severe symptoms from their advanced heart disease for extended periods [6].
Altogether these factors of high death rates and severe physical pain in HF patients produce results that match or surpass those found in patients with advanced metastatic cancer [7]; yet, palliative care integration into standard cardiology practice remains insufficient. Research shows that palliative care interventions improve outcomes for patients with HF by enhancing their quality of life, supporting caregivers, and facilitating communication. However, these interventions are not used as frequently as in oncology care [8, 9]. Primarily, this difference stems from healthcare providers and patients who believe palliative care means only end-of-life hospice care, although current definitions show that it works together with life-extending treatments starting at diagnosis [10].
Current clinical guidelines aim to connect these two areas. Both the 2021 European Society of Cardiology (ESC) guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) guidelines show a clear agreement that palliative care should function as a team-based system to treat physical, emotional and spiritual suffering throughout all HF stages [11, 12]. While supporting early integration, these two sets of guidelines maintain distinct approaches. It is crucial to acknowledge the distinctions between heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Disease-modifying treatment differs between HFrEF and HFpEF. The 2023 ESC Focused Update recommends sodium-glucose cotransporter 2 (SGLT2) inhibitors for symptomatic HFpEF to reduce the composite risk of HF hospitalization or cardiovascular death; the supporting trials primarily showed fewer HF events. Palliative needs should be assessed in both phenotypes [13]. Specifically, the European guidelines establish palliative care for advanced HF patients while providing specific instructions for symptom evaluation [11, 14]. In contrast, American guidelines establish two levels of palliative care delivery which include basic palliative skills for all cardiology clinicians and specialized palliative care services [5, 12]. However, implementation of these guidelines encounters multiple substantial obstacles. Referral processes face challenges because healthcare providers lack agreement about what conditions qualify patients for referral. Published approaches to palliative referral vary, and consistent implementation remains a challenge [10]. This absence of standardized referral criteria leads to a “care gap” because patients experience untreated dyspnea and pain and anxiety symptoms [15]. Furthermore, European countries experience multiple structural obstacles which prevent them from delivering complete HF care because of insufficient information sharing and unequal service availability between cities and towns and insufficient digital system integration [14].
Modern palliative practice for HF patients now extends past symptom control to handle intricate medical choices and future care planning [5]. Discussing patient prognosis and treatment objectives has become essential for all HF medical staff to learn. A clinician survey identified infrequent end-of-life discussions and barriers including discomfort, perceived patient or family unreadiness, and lack of time [16]. Such lack of communication becomes most important when patients need to stop using their implantable cardioverter-defibrillators (ICDs) before they die. Decisions about deactivating the shock function of ICDs at the end of life create emotional and ethical challenges. Failure to address device deactivation may expose patients to distressing shocks during their last days of life [17]. Therefore, the medical community needs immediate research synthesis to create practical guidelines which connect established treatment protocols to actual clinical practice [10, 14].
Aim
This review aims to provide a comprehensive analysis of the current state of palliative care in advanced heart failure. Specifically, we will examine evidence-based strategies for symptom management (dyspnea, pain, and depression), evaluate consensus criteria for specialist referral, and discuss the ethical and practical complexities of advance care planning and device deactivation. By integrating findings from recent systematic reviews and expert consensus statements, this article seeks to propose a practical framework for the timely integration of palliative care into the trajectory of heart failure.
Material and methods
This methodological framework was designed to ensure a comprehensive and reproducible analysis of the current evidence regarding palliative care integration in advanced HF [18]. A systematic literature search was conducted across primary electronic medical databases, including PubMed (MEDLINE), Embase, Scopus, and the Cochrane Library, covering the period from January 2000 to December 2024. This timeframe was selected to encompass the era of modern guideline-directed medical therapy (GDMT) and the emergence of specialized palliative cardiology. Specifically, the search strategy employed a Boolean logic-based combination of medical subject headings and free-text key words, including: “advanced heart failure”, “end-stage heart failure”, “palliative care”, “hospice”, “symptom burden”, “dyspnea”, “pain management”, and “advance care planning” [19, 20]. To maximize sensitivity, reference lists of retrieved systematic reviews and meta-analyses were manually screened for additional relevant studies that might have been omitted by the electronic search algorithms [21, 22].
Selection of eligible studies was governed by strict inclusion and exclusion criteria to maintain the internal validity of the review [23, 24]. Analysis included randomized controlled trials, observational cohort studies, and expert consensus statements published in the English language which focused on adult patients (aged 18 years or older) diagnosed with New York Heart Association (NYHA) class III or IV HF or American College of Cardiology/American Heart Association (ACC/AHA) stage D disease. Particular emphasis was placed on studies evaluating interventions related to symptom management, communication of prognosis, and models of care delivery. Studies involving pediatric populations, congenital heart defects, or those exclusively focused on surgical techniques without a supportive care component were excluded. Furthermore, case reports, editorials, and conference abstracts lacking peer-reviewed full-text data were omitted from the final analysis to ensure the reliability of the synthesized evidence [25, 26].
Data extraction and synthesis were performed qualitatively due to the anticipated heterogeneity in study designs, populations, and outcome measures, which precluded a formal statistical meta-analysis [27, 28]. Information regarding study design, sample size, intervention protocols, and primary outcomes (quality of life, hospital readmission rates, and mortality) was systematically extracted. Methodological quality of the included studies was appraised conceptually, distinguishing between high-evidence randomized trials and lower-evidence observational data [29]. Synthesis of results followed a narrative approach, grouping findings into thematic domains such as symptom pathophysiology, barriers to implementation, and the efficacy of interdisciplinary care models [30, 31]. This narrative synthesis informs the discussion while acknowledging heterogeneity in the evidence and the limitations of a qualitative review [32, 33].
Results
The systematic search initially yielded 1,245 records. After screening for eligibility, a total of 55 articles were included in the final narrative synthesis. The identified studies were categorized into three main thematic groups: epidemiology and prognosis (n = 12), symptom burden (n = 25; specifically focusing on dyspnea, pain, and depression), and implementation of concurrent care models (n = 18).
Demographic and epidemiological findings
Worldwide prevalence of HF keeps increasing because it now affects 64 million people globally [1]. In developed nations, the adult population shows HF prevalence at 1–2%, but numbers increase dramatically with age until they reach 10% or higher among people aged 70 and above [1]. Literature indicates that patients with advanced HF who have severe symptoms that do not respond to standard medical treatment make up 1–10% of all HF patients [34]. Multiple studies demonstrate that the “paradox of success” in contemporary cardiology leads to increased life expectancy because better acute coronary event survival and improved hypertension management allow patients to develop end-stage myocardial failure [2]. The growing prevalence of HF and associated healthcare expenditure represent substantial challenges for health systems [35].
Survival analysis and prognosis
Research studies demonstrate an unfavorable prognosis for this patient population because the disease progression remains unpredictable [5, 36]. A meta-analysis of chronic or stable HF in ambulatory settings reported pooled five-year survival of 56.7%; this estimate does not specifically describe Stage D HF [37]. Mortality rates for patients who fulfill the ACC/AHA Stage D criteria for advanced disease exceed those of other patient groups [34]. Acute decompensated HF is associated with substantial morbidity and mortality, although individual risk varies with disease severity, comorbidity, and treatment [15]. Survival estimates vary across HF populations and care settings, and community-based estimates should not be extrapolated directly to patients requiring continuous inotropic support or being assessed for advanced therapies [37]. Notably, the review includes studies that demonstrate HF survival rates after hospitalization are shorter than those seen in bowel, breast, and prostate cancer patients, thus proving the disease’s fatal nature [7]. Prognostic uncertainty complicates decision-making and supports repeated discussions of goals of care as the disease progresses [5].
Healthcare utilization and readmissions
Evidence shows hospital readmissions occur frequently which makes this metric the main reason for healthcare spending and an indicator of disease progression. In a United States all-payer analysis of HF hospitalizations during 2010–2017, all-cause readmission occurred in 18.2% of index admissions within 30 days and in 31.2% within 90 days [38]. These findings illustrate the substantial burden of recurrent hospitalization; the observational analysis does not establish that every admission causes permanent functional deterioration [38]. Hospital-based care accounts for a substantial proportion of healthcare resource use during the last six months of life among Medicare beneficiaries with HF [39]. Trials of integrated care have reported improvements in patient-centered outcomes. Inpatient palliative consultation improved symptom burden, quality of life, depressive symptoms, and advance care planning, but did not establish a preferred or actual place of death for all HF patients [40].
Symptom burden, frailty, and prevalence
Research on symptom prevalence shows that patients with end-stage HF experience severe physical and psychological distress which scientists call “total symptom distress” [41]. Dyspnea is a frequent distressing symptom, although reported prevalence varies with population, disease stage, and assessment method [41]. Heart failure symptom intensity shows unpredictable changes which differ from the expected decline in oncological patients. Pain is an important, potentially underrecognized symptom requiring assessment [42]. In a multicenter study of 96 veterans with HF, 53 patients (55.2%) reported pain and 36 (37.5%) rated it as moderate to severe. The cohort was 96% male, limiting generalization to all HF populations [43]. Multiple factors which cause pain in patients include swelling and insufficient blood flow to tissues and additional health issues such as osteoarthritis and gout [43]. Furthermore, the review demonstrates that frailty and cognitive dysfunction play essential roles in patient care beyond traditional heart and cardiorespiratory symptoms. In hospitalized adults aged at least 60 years with acute decompensated HF, Warraich et al. [4] reported frailty in 55% of patients with preserved and 52% with reduced ejection fraction, and cognitive impairment in 77% and 81%, respectively. These findings apply to the selected study cohort and should not be interpreted as prevalence estimates for the overall population of patients with advanced HF. A meta-analysis found clinically significant depression in 21.5% of HF patients, with substantial variation by assessment method and NYHA severity [44]. Depression and anxiety are associated with poorer adherence, hospitalization, and mortality [45]. Collectively, these symptoms lead to worse life quality and death rates in patients [45].
Discussion
Synthesizing epidemiological, prognostic, and symptom prevalence data presented in this review underscores a critical paradox in modern cardiology: while technological and pharmacological advancements have successfully extended the lifespan of patients with heart failure, they have simultaneously created a growing population living with a heavy burden of chronic, debilitating suffering [1, 2]. Results confirm that advanced HF is not merely a hemodynamic failure of the pump but a systemic, malignant syndrome comparable in its trajectory and symptom intensity to metastatic cancer [7]. This discussion integrates these findings to highlight the urgent necessity for a paradigm shift from a purely curative focus to a concurrent model of palliative care, addressing the multidimensional needs of both patients and their caregivers [10].
The malignancy of heart failure and prognostic paralysis: acute decompensation signals a period of increased clinical vulnerability and should prompt reassessment of prognosis, symptom burden, and goals of care [15]. While the transition to end-of-life care in oncology becomes evident through the absence of effective treatment options, HF progresses through a pattern of progressive deterioration with occasional worsening of symptoms [5]. Medical literature identifies this particular disease progression pattern as “prognostic paralysis.” Medical staff choose to postpone discussions about end-of-life care because they can use inotropes and mechanical circulatory support as salvage therapies [14]. Population-level survival estimates should inform, rather than replace, individualized prognostic communication [5]. Although the Seattle Heart Failure Model and Meta-Analysis Global Group in Chronic Heart Failure score serve as valid population-based prognostic tools, they do not offer practical guidance for advanced-stage patients who therefore adopt a passive observation strategy [36]. A lack of clear prognosis between patients hinders the prompt start of palliative care services, which results in patients being unready for their high risk of dying from cardiac arrest or HF [17]. Consequently, patients receive inappropriate life-extending treatments during their final days in hospital settings because their medical staff fails to understand their current treatment preferences [16].
Unaddressed symptom burden: the “silent epidemic” this review highlights frequent dyspnea and pain, with heterogeneous prevalence estimates across studies and a need for systematic symptom assessment [41, 42]. Given this prevalence, healthcare providers tending to ignore this symptom becomes concerning. Such high occurrence of pain in patients requires cardiologists to understand that pain results from multiple factors including skeletal muscle ischemia and neuropathies and edema-related discomfort [43]. Analgesic selection requires assessment of adverse effects and renal function; non-steroidal anti-inflammatory drugs are generally avoided in HF [42]. For refractory HF-related breathlessness, a 2023 meta-analysis found no demonstrated opioid benefit over <i><i>placebo</i></i> and more adverse effects, so routine opioid treatment is not supported [46] (Table 1).
Furthermore, symptoms such as thirst and xerostomia (dry mouth) present a significant problem for patients but receive little attention from medical professionals [47]. Research shows that HF patients experience severe thirst problems because they must restrict their fluid intake and take high doses of loop diuretics. Assessment of thirst occurs infrequently in standard checklists although it creates substantial deterioration in patients’ life quality [47]. Total symptom distress receives additional impact from psychological symptoms. Depression and anxiety are common in HF and are associated with poorer adherence and adverse clinical outcomes through behavioral and physiological pathways. Their prevalence depends on the population and diagnostic method [44, 45]. Current healthcare approaches that separate heart treatment from mental health care fail to handle the interconnected symptoms which create a downward spiral of worsening symptoms [45].
A primary obstacle to palliative care integration stems from the existing “culture of rescue” which dominates in cardiology practice. Medical training of cardiologists focuses on using new technological tools to combat death [10]. Medical staff view palliative care as a sign of surrender because they believe it represents a breakdown in their ability to treat patients [14]. Barriers to timely discussions and referral can delay supportive care despite existing symptom and communication needs [10, 16]. Implementing supportive care needs a fundamental change in medical practice because it should receive equal status to -blockade and neurohormonal inhibition (e.g., angiotensin-converting enzyme inhibitors or angiotensin receptor-neprilysin inhibitors as an essential cardiology treatment) [14].
The ethical dilemma of implantable devices
A distinct element of advanced HF treatment in this discussion involves the management of ICDs. While functioning as life-savers when patients first receive them, they create major ethical and humanitarian problems during end-of-life care. Risk of the device delivering painful shocks becomes more likely when patients develop pump failure that leads to death [17]. In a qualitative study of 15 ambulatory ICD recipients, no participant had discussed deactivation with a physician or knew it was an option. This small study illustrates communication barriers but does not establish their prevalence in all ICD recipients [17]. Lack of proper advance care planning for device management during stable clinic visits instead of emergency situations leads to avoidable patient distress and makes it harder for families to cope with their loss.
The economic, systemic, and caregiver imperative
This “revolving door” phenomenon, illustrated by substantial 30- and 90-day readmission rates, represents not only a failure of disease management but a crisis of healthcare sustainability [38]. The substantial use of hospital-based services near the end of life highlights the economic consequences of a predominantly reactive approach [39]. The Palliative Care in Heart Failure trial demonstrated improvements in quality of life, anxiety, depression, and spiritual well-being, but did not demonstrate a reduction in rehospitalization or mortality [8]. A systematic review of randomized trials found that palliative care interventions were associated with fewer hospitalizations, although the included studies had methodological limitations [48].
Moreover, the discussion must acknowledge the profound burden on informal caregivers, often referred to as the “hidden patients” [49]. Complexity of advanced HF regimens – requiring strict dietary adherence, daily weighing, and complex medication schedules – coupled with the emotional toll of watching a loved one decline, leads to high rates of caregiver burnout. A population-based study found substantial unmet needs among HF caregivers and lower access to specialist palliative care than among caregivers for other conditions, particularly cancer [49]. Social support is associated with outcomes in HF, supporting attention to caregiver well-being; these associations do not establish that caregiver exhaustion independently causes readmission [50].
Frequent frailty and cognitive impairment in older hospitalized HF patients support careful assessment of treatment tolerance and self-care needs [4]. Evidence supporting neurohormonal blockade treatment originated from research conducted on patients who were younger and less frail. Elderly patients in this review experience deteriorating quality of life because they follow blood pressure targets and take multiple medications which lead to orthostatic hypotension and falls and worsen their renal function [51]. Defining optimal treatment for advanced patients requires modification because of their specific needs. Medication review may support withdrawal of non-essential preventive treatment, such as statins, when anticipated benefit is unlikely within the patient’s remaining lifespan. Decisions about anticoagulation require individualized assessment of the indication, thromboembolic risk, bleeding risk, prognosis, and patient preferences [51].
Bridging the gap: the concurrent care model evidence from this study demonstrates that palliative care should not start only after patients stop receiving life-extending treatments [10]. Furthermore, research supports the implementation of a “concurrent care” model. It demonstrates that HF specialists need to develop basic palliative care competencies which include symptom control and communication abilities because patients with HF experience severe symptoms and their death risk remains unpredictable [15]. Healthcare systems need to create “trigger tools” which function as checklists that activate palliative care evaluations [14]. Recurrent admissions, worsening function, cachexia, persistent symptoms, and dependence on advanced support can prompt a palliative needs assessment. Such indicators support clinical judgment rather than constitute a universally validated automatic referral algorithm [14]. Such systems should use specific clinical markers to request palliative care consultations instead of waiting for patients to reach the end of their life. Additionally, the system needs to unite these two medical approaches to deliver complete care for patients who need physical, psychological and existential support [52].
Conclusions
This comprehensive review of the epidemiological, clinical, and systemic data presented in this work leads to a fundamental reevaluation of the current management strategies for advanced heart failure. Evidence synthesized in the preceding chapters demonstrates unequivocally that the traditional, purely curative model of cardiology is insufficient to address the complex needs of this growing patient population. Advanced HF must be reframed not merely as a hemodynamic disorder treatable with pharmacological titration, but as a systemic, malignant syndrome that requires a concurrent, multidisciplinary approach integrating palliative care from the point of diagnosis of advanced disease [10, 52].
Synthesis of the clinical imperative research findings demonstrate that advanced HF progression produces death risks and symptoms which match or surpass those found in metastatic cancer patients [7]. This study reveals that clinical decision-making faces a major obstacle because doctors lack clear understanding about how the disease will progress [5]. Combining treatment uncertainty with cardiology’s rescue-oriented approach leads to widespread end-of-life overtreatment through ineffective aggressive interventions which contradict patient wishes [16]. Research shows that advanced HF patients experience multiple symptoms beyond their traditional symptoms of dyspnea, fatigue and edema [41]. High occurrence of unidentifiable symptoms including chronic pain, xerostomia and anxiety requires healthcare providers to expand their treatment approach [43, 47]. Frailty and cognitive impairment warrant individualized monitoring, assessment of treatment tolerance, and support for self-care; they do not by themselves justify withdrawal of beneficial GDMT [4, 51]. Evidence suggests that advanced HF treatment should focus on individualized care which emphasizes symptom management and maintenance of functional abilities instead of pursuing maximum neurohormonal blockade [51].
Recommendations for clinical practice: the following recommendations for clinical HF management stem from the evidence assessment:
First, healthcare organizations need to shift away from separate treatment approaches which view palliative care as opposing to life-extending medical therapy. Organizations should establish a standardized “concurrent care” model which delivers palliative services together with maximum cardiac treatment [10]. This method enables doctors to perform intensive treatment for HF causes that can be reversed while providing patients with symptom relief and end-of-life care planning.
Standard cardiological assessment templates need expansion to include non-cardiac symptom screening which affects patients’ quality of life. The brief pain inventory should be used to assess pain while the nine-item patient health questionnaire (PHQ-9) should be used to screen for depression and distressing thirst should be evaluated at the same level as blood pressure and ejection fraction measurements [42, 44, 47]. Heart failure treatment requires patients to receive standard management for these symptoms.
Utilization of clinical indicators for palliative referral: recurrent HF admissions, substantial weight loss or cachexia, dependence on inotropic support, deteriorating function, and persistent symptoms despite appropriate HF treatment should prompt assessment of palliative needs. Prognostic prompts such as the surprise question can support discussion, but should not be treated as stand-alone validated automatic referral rules [14].
Proactive device management: discussion of ICD shock deactivation for patients with Stage D HF should become a standard part of regular care review, with deactivation considered when consistent with the patient’s goals and informed preferences [17]. Medical facilities need to create procedures which allow patients to understand their ability to disable shock functionality while keeping pacemaker operations active when their treatment priorities change to comfort care.
Systemic and educational implications: research indicates that cultural and educational barriers stand as the main obstacles which prevent palliative care integration [10]. Consequently, the following changes need to occur in the system: medical schools and cardiology fellowship programs need to establish compulsory training for basic palliative care skills which include serious illness communication and prognostication, and pharmacologic treatment of dyspnea and pain. Training should address evidence limitations and adverse effects of opioids for refractory breathlessness. Exceptional use requires individualized specialist assessment after other measures have failed [46]. Healthcare providers need to establish formal procedures for assessing the amount of work caregivers handle [49]. The heart failure care bundle should include reimbursement for respite care and dedicated caregiver education programs to stop caregiver burnout which leads to patient readmissions. Telemedicine platforms need to provide palliative care services through remote consultations and symptom tracking to patients who stay at home because of their limited mobility. Finally, the system should use telemedicine to provide palliative care services at home instead of requiring patients to travel to medical facilities for treatment [52].
Future research directions: while the evidence for palliative care in HF is growing, significant gaps remain that require targeted investigation. Deprescribing protocols: rigorous randomized trials are needed to establish safe and effective protocols for the downtitration (“deprescribing”) of cardiovascular medications in the end-of-life phase. Research should determine which medications can be safely withdrawn to reduce pill burden and side effects without precipitating acute decompensation [9]. Interventions for cognitive impairment: given the high prevalence of cognitive dysfunction, research is needed to develop advance care planning tools specifically designed for patients with executive function deficits, ensuring their values are respected even as decision-making capacity declines [4]. The role of SGLT2 inhibitors in palliation: these agents improve HF outcomes, but benefits differ by endpoint and population. Their role in patients specifically receiving end-of-life care requires further study [13]. Health economics of concurrent care: further data are needed to quantify the cost-effectiveness of early palliative integration, specifically analyzing the reduction in intensive care unit days and futile interventions, to drive policy changes and reimbursement reform.
Final conclusion: advanced HF stands as a major public health concern because it leads to high death rates and unpredictable disease progression and severe symptoms that affect patients. Findings from this review show that palliative care integration serves as proof of excellent patient-focused medical practice rather than indicating treatment failure [10]. Concurrent care offers a patient-centered approach to multidimensional suffering alongside appropriate HF treatment. Cardiology needs to recognize palliative care as an essential combatant against HF at this critical moment [52].
Disclosures
1. Institutional review board statement: Not applicable.
2. Assistance with the article: None. 3. Financial support and sponsorship: None. 4. Conflicts of interest: None.
References
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023; 118: 3272-3287.
- Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep 2014; 11: 404-415.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133: e38-360.
- Warraich HJ, Kitzman DW, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, et al. Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥ 60 years with acute decompensated heart failure with preserved <i><i>versus</i></i> reduced ejection fraction. Circ Heart Fail 2018; 11: e005254.
- Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125: 1928-1952.
- Mentz RJ, O’Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 2016; 13: 28-35.
- Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes 2010; 3: 573-580.
- Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol 2017; 70: 331-341.
- McIlvennan CK, Allen LA. Palliative care in patients with heart failure. BMJ 2016; 353: i1010.
- Kavalieratos D, Gelfman LP, Tycon LE, Riegel B, Bekelman DB, Ikejiani DZ, et al. Palliative care in heart failure: rationale, evidence, and future priorities. J Am Coll Cardiol 2017; 70: 1919-1930.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145: e895-e1032.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627-3639.
- Sobanski PZ, Alt-Epping B, Currow DC, Goodlin SJ, Grodzi-cki T, Hogg K, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 2020; 116: 12-27.
- Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. Curr Cardiol Rev 2015; 11: 53-62.
- Dunlay SM, Foxen JL, Cole T, Feely MA, Loth AR, Strand JJ, et al. A survey of clinician attitudes and self-reported practices regarding end-of-life care in heart failure. Palliat Med 2015; 29: 260-267.
- Goldstein NE, Mehta D, Siddiqui S, Teitelbaum E, Zeidman J, Singson M, et al. “That’s like an act of suicide” patients’ attitudes toward deactivation of implantable defibrillators. J Gen Intern Med 2008; 23 Suppl 1: 7-12.
- Snyder H. Literature review as a research methodology: an overview and guidelines. J Bus Res 2019; 104: 333-339.
- McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016; 75: 40-46.
- Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev 2017; 6: 245.
- Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 2021; 10: 39.
- Greenhalgh T. Papers that summarise other papers (systematic reviews and meta-analyses). BMJ 1997; 315: 672-675.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
- Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169: 467-473.
- Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J 2009; 26: 91-108.
- Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs 2005; 52: 546-553.
- Baumeister RF, Leary MR. Writing narrative literature reviews. Rev Gen Psychol 1997; 1: 311-320.
- Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011; 31: 1409-1417.
- Ferrari R. Writing narrative style literature reviews. Medical Writing 2015; 24: 230-235.
- Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005; 8: 19-32.
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated August 2022). Cochrane 2022. Available from: https://www.cochrane.org/authors/handbooks-and-manuals/handbook.
- Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 2015; 13: 141-146.
- Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20: 1505-1535.
- Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 2021; 143: e254-e743.
- Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
- Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 2019; 21: 1306-1325.
- Khan MS, Sreenivasan J, Lateef N, Abougergi MS, Greene SJ, Ahmad T, et al. Trends in 30- and 90-day readmission rates for heart failure. Circ Heart Fail 2021; 14: e008335.
- Unroe KT, Greiner MA, Hernandez AF, Whellan DJ, Kaul P, Schulman KA, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med 2011; 171: 196-203.
- Sidebottom AC, Jorgenson A, Richards H, Kirven J, Sillah A. Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial. J Palliat Med 2015; 18: 134-142.
- Janssen DJ, Spruit MA, Wouters EF, Schols JM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med 2008; 22: 938-948.
- Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol 2009; 54: 386-396.
- Goebel JR, Doering LV, Shugarman LR, Asch SM, Sherbour- ne CD, Lanto AB, et al. Heart failure: the hidden problem of pain. J Pain Symptom Manage 2009; 38: 698-707.
- Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48: 1527-1537.
- Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry 2018; 26: 175-184.
- Gaertner J, Fusi-Schmidhauser T, Stock S, Siemens W, Venne dey V. Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis. Heart 2023; 109: 1064-1071.
- Waldréus N, Hahn RG, Jaarsma T. Thirst in heart failure: a systematic literature review. Eur J Heart Fail 2013; 15: 141-149.
- Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail 2020; 22: 2340-2346.
- Davidson PM, Abernethy AP, Newton PJ, Clark K, Currow DC. The caregiving perspective in heart failure: a population based study. BMC Health Serv Res 2013; 13: 342.
- Luttik ML, Jaarsma T, Moser D, Sanderman R, van Veldhui- sen DJ. The importance and impact of social support on outcomes in patients with heart failure: an overview of the literature. J Cardiovasc Nurs 2005; 20: 162-169.
- Martínez-Sellés M, Grodzicki T. Modification of cardiovascular drugs in advanced heart failure: a narrative review. Front Cardiovasc Med 2022; 9: 883669.
- Braun LT, Grady KL, Kutner JS, Adler E, Berlinger N, Boss R, et al. Palliative care and cardiovascular disease and stroke: a policy statement from the American Heart Association/American Stroke Association. Circulation 2016; 134: e198-225.